Clinical biomarkers in hepatocellular carcinoma (HCC)

Frontiers in Bioscience - Scholar

Volumn 2 S, Issue 2, 2010, Pages 571-577

  Donati, Marcello ^a   Brancato, Giovanna ^a   Donati, Angelo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

Biomarkers; Bioumoral screening; HCC; Hepatocellular carcinoma; Review

Indexed keywords

AFP PROTEIN, HUMAN; ALPHA FETOPROTEIN; ALPHA LEVO FUCOSIDASE; BIOLOGICAL MARKER; DECARBOXYPROTHROMBIN; GLYPICAN; LENTIL LECTIN; PLANT LECTIN; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; REVIEW;

ALPHA-FETOPROTEINS; ALPHA-L-FUCOSIDASE; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; GLYPICANS; HUMANS; LIVER NEOPLASMS; PLANT LECTINS; PROTEIN PRECURSORS; PROTHROMBIN; TUMOR MARKERS, BIOLOGICAL;

EID: 77957298307     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s86     Document Type: Review

References (57)

1. El-Serag H.B., Davila JA, Petersen N.J., McGlynn KA: The continuing increase in the incidence of hepatocellular carcinoma in United States: An update. Ann. Intern. Med, 139, 817-23 (2003)
2. Bruix J, Sherman M, Llovet J.M., Beaugrand M., Lencioni R, Burroughs AK, Christensen E, Pagliaro L., Colombo M, Rodés J; EASL Panel of Experts on HCC: Clinical management of hepatocellular carcinoma: Conclusions of the Barcelona-2000 EASL conference; European Association for the study of the Liver. J. Hepatol, 35, 421-30 (2001) (Pubitemid 32844200)
3. Yoon Sk: Recent advances in tumor markers of human hepatocellular carcinoma. Intervirology, 51 (suppl. 1),34-41, (2008)
4. World Health Organization. Mortality database. Available from: URL: http//www.who.int/whosis/en/
5. El-Serag HB: Epidemiology of hepatocellular carcinoma in USA. Hepatol. Res, 37, S88-94 (2007)
6. Davila JA, Morgan RO, Shaib Y, McGlynn K.A., El-Serag HB: Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology, 127, 1372-80, (2004) (Pubitemid 39457763)
7. Marrero J.A: Hepatocellular carcinoma. Curr. Opin. Gastroenterol, 22, 248-53 (2006) (Pubitemid 44090061)
8. Schacherer D, Schoelmerich J, Zuber-Jerger I: Diagnostik des hepatozellulären Karzinoms. Z. Gastroenterol, 45, 1067-74 (2007)
9. Abelev G, Perova S, Khramkova Z., Irlin I. Production of embryonal alpha-globulin by transplantable mouse hepatoma. Transplantation, 1, 174-80, (1963)
10. Saffroy R, Pham P, Reffas M., Takka M, Lemoine A, Debuire B: New perspectives and strategy research biomarkers for hepatocellular carcinoma. Clin. Chem. Lab. Med, 45 (9),1169-79, (2007) (Pubitemid 47396274)
11. Trevisani F, D'Intino PE, Morselli-Labate AM, Mazzella G., Accogli E, Caraceni P, Domenicali M., De Notariis S, Roda E, Bernardi M: Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J. Hepatol, 34, 570-5 (2001) (Pubitemid 32328514)
12. Llovet JM: Hepatocellular carcinoma: patients with increasing alpha-fetoprotein but no mass on ultrasound. Clin. Gastroenterol. Hepatol, 4, 29-35 (2006) (Pubitemid 43129520)
13. Daniele B, Bencivenga A, Megna A.S., Tinessa V: Alpha-fetoprotein and ultrasonography screening for hepatocellular carcinoma. Gastroenterology, 127 (5 Suppl),108-112 (2004)
14. Farinati F, Marino D, De Giorgio M, Baldan A, Cantarini M., Cursaro C, Rapaccini G, Del Poggio P, Di Nolfo MA, Benvegnù L, Zoli M, Borzio F, Bernardi M, Trevisani F: Diagnostic and prognostic role of α-fetoprotein in hepatocellular carcinoma: both or neither? Am. J. Gastroenterol, 101, 524-32 (2006) (Pubitemid 43340928)
15. Bruix J, Sherman M: Practice Guidelines Committee American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology, 42, 1208-36, (2005)
16. Franca AV, Elias Junior J, Lima BL, Martinelli A.L., Carrilho FJ: Diagnosis, staging and treatment of hepatocellular carcinoma. Braz. J. Med. Biol. Res, 37, 1689-1705 (2004) (Pubitemid 39555461)
17. Collier J, Sherman M: Screening for hepatocellular carcinoma. Hepatology, 27, 273-8 (1998) (Pubitemid 28041564)
18. Okuda K: Early recognition of hepatocellular carcinoma. Hepatology, 6, 729-38 (1986) (Pubitemid 16038197)
19. Sherman M: Alpha-fetoprotein: an obituary. J. Hepatol, 34, 6035 (2001)
20. Forner A, Reig M, Bruix J: Alpha-fetoprotein for hepatocellular carcinoma diagnosis: the desmise of a brilliant star. Gastroenterology, 137 (1),26-9 (2009)
21. Tang ZY: Primary hepatocellular carcinoma. In: Tang ZY, editor. Contemporary oncology. (Chinese) Shanghai: Shanghai Medical University, 554-85, (1993)
22. D. Li, T. Mallory, S. Satomura: AFP-L3: a new generation of tumour marker for hepatocellular carcinoma. Clin. Chim. Acta, 313, 15-19, (2001) (Pubitemid 33016686)
23. Kumada T, Nakano S, Takeda I., Kiriyama S, Sone Y, Hayashi K., Katoh H, Endoh T, Sassa T., Satomura S: Clinical utility of lens culinaris agglutinin-reactive alpha-fetoprotein in small hepatocellular carcinoma: special reference to imaging diagnosis. J Hepatol, 30, 125-30 (1999) (Pubitemid 29023661)
24. Yamashiki N, Seki T, Wakabayashi M., Nakagawa T, Imamura M, Tamai T., Nishimura A, Inoue K, Okamura A., Arita S, Harada K: Usefulness of lens culinaris agglutinin a-reactive fraction of a-Fetoprotein (AFP-L3)as a marker of distant metastasis from hepatocellular carcinoma. Oncol Rep, 6, 1229-32, (1999)
25. Suzuki M, Shiraha H, Fujikawa T., Takaoka N, Ueda N, Nakanishi Y., Koike K, Takaki A, Shiratori Y: Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J. Biol. Chem, 280, 6409-15, (2005) (Pubitemid 40341187)
26. Liebman HA, Furie BC, Tong M.J., Blanchard RA, Lo KJ, Lee SD, Coleman M.S., Furie B. Des-gamma-carboxy (abnormal)prothrombin as a serum marker of primary hepatocellular carcinoma. N. Engl. J. Med, 310, 1427-31 (1984) (Pubitemid 14101298)
27. Izuno K, Fujiyama S, Yamasaki K., Sato M, Sato T: Early detection of hepatocellular carcinoma associated with cirrhosis by combined assay of des-gamma-carboxy prothrombin and alpha-fetoprotein: a prospective study. Hepatogastroenterology, 42, 387-93, (1995)
28. Wang CS, Lin CL, Lee H.C., Chen KY, Chiang MF, Chen HS, Lin T.J., Liao LY: Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. World J. Gastroenterol, 11, 6115-9 (2005)
29. Marrero JA, Su GL, Wei W, Emick D., Conjeevaram HS, Fontana RJ, Lok AS: Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from non-malignant chronic liver disease in American patients. Hepatology, 37, 1114-21 (2003) (Pubitemid 36538688)
30. Shimizu A, Shiraki K, Ito T., Sugimoto K, Sakai T, Ohmori S., Murata K, Takase K, Tameda Y., Nakano T: Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high - sensitive electrochemiluminescence system as an early predictive marker of hepatocellular carcinoma in patients with cirrhosis. Int. J. Mol. Med, 9, 245-50, (2002)
31. Kudo M: Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology, 75 (suppl 1),1-12 (2008)
32. Bolondi L, Sofia S, Siringo S., Gaiani S, Casali A, Zironi G., Piscaglia F, Gramantieri L, Zanetti M., Sherman M: Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectivness analysis. Gut, 48, 251-9 (2001) (Pubitemid 32141852)
33. Makuuchi M, Kokudo N, Arii S., Futagawa S, Zaki M, Okita K., Omata M, Saida Y, Takayama T., Yamaoka Y: Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol. Res, 38, 37-51 (2008) (Pubitemid 350182575)
34. Haydon GH, Hayes PC: Screening of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol, 8, 856-60, (1996)
35. Ishizuka H, Nakayama T, Matsuoda S., Gotoh I, Ogawa M, Suzuki K., Tanaka N, Tsubaki K, Okhubo H., Arakawa Y, Okano T: Prediction of the development of hepatocellular carcinoma in patients with liver cirrhosis by the serial determinations of serum alpha-L-fucosidase activity. Intern. Med, 38, 927-31, (1999)
36. Tangkijvanich P, Tosukhowong P, Bunyongyod P., Lertmaharit S, Hanvivatvong O, Kullavanijaya P., Poovorawan Y: Alpha-l-fucosidase as a serum marker of hepatocellular carcinoma in Thailand. Southeast Asian J Trop med Public Health, 30, 110-4 (1999)
37. Giardina MG, Matarazzo M, Morante R., Lucariello A, Varriale A, Guardasole V., De Marco G: Serum alpha-l-fucosidase activity and early detection of hepatocellular carcinoma: a prospective study of patients with cirrhosis. Cancer, 83, 2468-74 (1998) (Pubitemid 29019564)
38. Abdel-Aleem H., Ahmed A, Sabra A.M., Zakhari M., Soliman M, Hamed H: Serum alpha-l-fucosidase enzyme activity in ovarian and other female genital tract tumors. Int. J. Gynaecol. Obstet, 55, 273-9 (1996) (Pubitemid 27007611)
39. Ayude D, Fernandez-Rodriguez J, Rodriguez-Berrocal FJ, Martinez-Zorzano VS, de Carlos A, Gil E, Paez de la Cadena M.: Value of the serum alpha-l-fucosidase activity in the diagnosis of colrectal cancer. Oncology, 59, 310-6 (2000)
40. Bernfield M, Gotte M, Park P.W., Reizes O., Fitzgerald ML, Lincecum J, Zako M: Functions of cell surface heparan sul fate proteoglycans. Annu. Rev. Biochem, 68, 729-777, (1999) (Pubitemid 29449208)
41. Capurro M, Wanless IR, Sherman M, Deboer G., Shi W, Miyoshi E, Filmus J: Glypican-3: a novel serum and histochemical marker of hepatocellular carcinoma. Gastroenterology, 125, 89-97, (2003) (Pubitemid 36799110)
42. Kandil DH, Cooper K: Glypican-3: a novel diagnostic marker for hepatocellular carcinoma and more. Adv. Anat. Pathol, 16 (2),125-9, (2009)
43. Nakatsura T, Kageshita T, Ito S., Wakamatsu K, Monji M, Ikuta Y., Senju S, Ono T, Nishimura Y: Identification of Glypican-3 as a novel tumor marker for melanoma. Clin. Cancer Res, 10, 6612-21, (2004) (Pubitemid 39346558)
44. Song HH, Shi W, Filmus J: OCI-5/rat glypican-3 binds to fibroblast growth factor-2 but not to insulin-like growth factor-2. J. Biol. Chem, 272, 7574-7, (1997) (Pubitemid 27137302)
45. Pilia G, Hughes-Benzie RM, MacKenzie A., Baybayan P, Chen EY, Huber R, Neri G., Cao A, Forabosco A, Schlessinger D: Mutations in GPC-3, a glypican gene, cause the Simpson-Golabi-Behmel overgrowth syndrome. Nat. Genet, 12, 241-7, (1996) (Pubitemid 26080081)
46. Liu B, Paranjpe S, Bowen W.C., Bell AW, Luo JH, YU YP, Michalopoulos GK: Investigation of the role of Glypican-3 in liver regeneration and Hepatocyte proliferation. Am. J. Pathol, 175 (2),717-24, (2009)
47. Hippo Y, Watanabe K, Watanabe A., Midorikawa Y, Yamamoto S, Ihara S., Tokita S, Iwanari H, Ito Y., Nakano K, Nezu J, Tsunoda H, Yoshino T, Ohizumi I, Tsuchiya M, Ohnishi S, Makuuchi M, Hamakubo t, Kodama T, Aburatani H: Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early stage hepatocellular carcinoma. Cancer Res, 64, 2418-23, (2004) (Pubitemid 38523895)
48. Ligato S, Mandlich D, Cartun RW: Utility of glypican-3 in differentiating hepatocellular carcinoma from other primary and metastatic lesions in FNA of the liver an immunocytological study. Mod. Pathol, 21, 626-31 (2008) (Pubitemid 351589657)
49. Nassar A, Cohen C, Siddiqui MT: Utility of Glypican-3 and survivin in differentiating hepatocellular carcinoma from benign and preneoplastic hepatic lesions and metastatic carcinomas in liver fine-needle aspiration biopsies. Diagn. Cytopathol, 37 (9),629-35 (2009)
50. Shirakawa H, Suzuki H, Shimomura M., Kojima M, Gotohda N, Takahashi S., Nakagohri T, Konishi M, Kobayashi N., Kinoshita T, Nakatsura T: Glypican-3 espression is correlated with poor prognosis in hepatocellular carcinoma. Cancer Sci, 100 (8),1403-7 (2009)
51. Kato H, Suehiro Y, Morioka H., Torigoe T, Myoga A, Sekiguchi K., Ikeda I: Heterogeneous distribution of acid TA-4 in cervical squamous cell carcinoma: Himmunohistochemical demonstration with monoclonal antibodies. Jpn. J. Cancer Res, 78, 1246-50 (1987) (Pubitemid 18012968)
52. Pontisso P, Calabrese F, Benvegnù L, Lise M, Belluco C, Ruvoletto MG, Marino M, Valente M, Nitti D, Gatta A, Fassina G: Overexpression of squamous cell carcinoma antigen variants in hepatocellular carcinoma. Br. J. Cancer, 90, 833 (2004)
53. Giannelli G, Marinosci F, Sgarra C., Lupo L, Sentico P, Antonaci S: Clinical role of tissue and serum levels of SCCA antigen in hepatocellular carcinoma. Int. J. Cancer, 116 (4),579-83 (2005) (Pubitemid 41099194)
54. Hussein MM, Ibrahim AA, Abdella H.M., Montasser IF, Hassan MI: Evaluation of serum squamous cell carcinoma antigen as a novel biomarker for diagnosis of hepatocellular carcinoma in Egyptian patients. Indian J. Cancer, 45 (4),167-72 (2008)
55. Giannelli G, Fransvea E, Trerotoli P., Beaugrand M, Marinosci F, Lupo L., Nkontchou G, Dentico P, Antonaci S: Clinical validation of combined serological biomarkers improved hepatocellular carcinoma diagnosis in 961 patients. Clin. Chim. Acta, 383, 147-52 (2007) (Pubitemid 47016463)
56. Beale G, Chattopadhyay D, Gray J., Stewart S, Hudson M, Day C., Trerotoli P, Giannelli G, Manas D., Reeves H: AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease. BMC Cancer, 8, 200, (2008)
57. Trerotoli P, Fransvea E, Angelotti U., Antonaci G, Lupo L, Mazzocca A., Mangia A, Antonaci S, Giannelli G: Tissue expression of Squamous Cell Carcinoma Antigen (SCCA) is inversely correlated to tumor size in HCC. Molecular Cancer, 27 (8),29, (2009)